Comparison · NCT02184195-495cbdb9
Olaparib 300 mg Twice Daily (bd) vs Placebo: Number of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.1
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Olaparib 300 mg Twice Daily (bd) vs Placebo: Number of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.1. Trial comparisons, record NCT02184195-495cbdb9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02184195-495cbdb9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.306 | 0.211 | 0.42 | wilson | |
| Risk in group 2 | 0.224 | 0.13 | 0.359 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0811 | -0.083 | 0.229 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.36 | 0.728 | 2.55 | log | |
| Odds ratio, group 1 over group 2 | 1.52 | 0.658 | 3.51 | log | |
| Number needed to treat, for one more participant with the outcome on Olaparib 300 mg Twice Daily (bd) than on Placebo | 12.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Olaparib 300 mg Twice Daily (bd) | Randomised participants received orally 300 mg bd which were made up of 2 x 150 mg tablets bd with 100 mg tablets used to manage dose reductions. | 22 | 72 | OG000 |
| Group 2 | Placebo | Randomised participants received placebo tablets orally 300 mg bd which were made up of 2 x 150 mg tablets bd with 100 mg tablets used to manage dose reductions. | 11 | 49 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.1
- Description
To determine efficacy by assessment of objective response rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo. The ORR is defined as the number of with a BoR of CR and PR according to the BICR data divided by the number of patients in the treatment group with measurable disease at baseline.
- Time frame
- Up to 4 years
- Population
- All randomised patients with measurable disease at baseline.
Source ClinicalTrials.gov
Trial
- Title
- Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
- NCT number
- NCT02184195
- Phases
- PHASE3
- Conditions
- Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
- Interventions
- Olaparib, Olaparib, Placebo, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2020-01-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02184195?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02184195-495cbdb9